clinical trial · NCT05538689
Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)
University of Chicago·phase4·withdrawn
MetrorrhagiaPelvic PainMenorrhagiaLeiomyomaMyfembree Oral Product
brief summary
In this project, the proposition is that the use of daily dosed Myfembree ( a combination of relugolix with estradiol and norethindrone acetate), FDA-approved medication to treat heavy menses fibroid-related symptoms, has the potential to delay the recurrence of fibroid symptoms, prolong the improved quality of life and delay the need for re-intervention after uterine sparing surgery versus the routine standard of care.
started
Nov 20, 2022
primary completion
Oct 24, 2024
completion
Oct 24, 2024
last updated
Sep 29, 2025
official title
Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol